TSON, SMED, UEC and NURO: All 4 penny stocks and all 4 good stocks to buy now, February 28, 2012, all upgraded or initiated coverage to a “buy” rating or better recently from Wall Street analysts and all under $4:
TranS1 Inc. (NASDAQ: TSON), a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine affecting the lower lumbar region, was upgraded by analysts at Canaccord Genuity from a “hold” rating to a “buy” rating. TSON closed Monday, February 27, 2012 at $2.81, up +0.34 (+13.77%) on volume of 255,586. TSON is trading:
- 21.34% above its 50-Day Moving Average, 2.32,
- 7.66% above its 200-Day Moving Average, 7.61,
- in the middle of its 52-Week Range of 1.39 – 5.42,
- with a Short Ratio of 0.20
Canaccord Genuity now have a $3.50 price target on TSON, up previously from $3.00.
Initiated Coverage
Sharps Compliance (NASDAQ: SMED), a leading full-service provider of cost-effective management solutions for medical waste and unused dispensed medications generated outside the hospital and large healthcare facility setting, is now covered by analysts at Wunderlich. SMED closed Monday, February 27, 2012 at $3.83, up +0.03 (+0.79%) on volume of 35,447. SMED is trading:
- 0.13% above its 50-Day Moving Average, 3.83,
- -4.80% below its 200-Day Moving Average, 4.02,
- in the middle of its 52-Week Range of 2.66 – 5.79,
- with a Short Ratio of 18.10
Wunderlich set a “buy” rating and a $7.50 price target on SMED.
Uranium Energy (NYSE: UEC), a U.S.-based uranium production, development and exploration company operating North America’s newest emerging uranium mine, is now covered by analysts at MLV & Co. UEC closed Monday, February 27, 2012 at $3.96, down -0.10 (-2.46%) on volume of 501,043. UEC is trading:
- 3.79% above its 50-Day Moving Average, 3.82,
- 21.75% above its 200-Day Moving Average, 3.25,
- past the middle of its 52-Week Range of 2.20 – 6.14,
- with a Short Ratio of 19.70
MLV & Co. set a “buy” rating and a $5.50 price target on UEC.
NeuroMetrix, Inc. (NASDAQ: NURO), a science-based health care company improving patient care through neurotechnology founded in 1996 as MIT/Harvard Medical School spin-off, is now covered by analysts at Dawson James. NURO closed Monday, February 27, 2012 at $0.7902, up +0.01 (+1.31%) on volume of 216,558. NURO is trading:
- -32.92% below its 50-Day Moving Average, 1.18,
- -52.25% below its 200-Day Moving Average, 1.65,
- near the bottom of its 52-Week Range of 0.75 – 3.78,
- with a Short Ratio of 4.10
Dawson James set a “buy” rating and a $3.00 price target on NURO.
Fundamental company data provided by Capital IQ:
Subscribe to AimHighProfits FREE stock alerts to get the latest Small and Mid Cap Stock Alerts.
ShareFEB
